We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

16 hedge funds and large institutions have $43.5M invested in Viridian Therapeutics in 2017 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 2 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67,123% more capital inflows, than outflows

Capital inflows: $39.7M | Capital outflows: $59K

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

100% more funds holding

Funds holding: 8 → 16 (+8)

16.35% more ownership

Funds ownership: 0% → 16.35% (+16%)

Holders
16
Holders Change
+8
Holders Change %
+100%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
2
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$35.9M
2
University of Texas/Texas AM Investment Management Co (UTIMCO)
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
+$1.21M
3
Millennium Management
Millennium Management
New York
+$750K
4
Goldman Sachs
Goldman Sachs
New York
+$746K
5
Dowling & Yahnke
Dowling & Yahnke
California
+$460K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$53K
2
Deutsche Bank
Deutsche Bank
Germany
-$5K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1K

VRDN Hedge Fund Activity: Q1 2017 in Review

16 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2017, worth a combined $43.5M — up 15,047% from $287K a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new VRDN positions and 3 closed out — a net gain of 9 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $35.9M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $53K sold.

  • 16 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2017, up from 8 in Q4 2016.
  • Funds reported $43.5M of Viridian Therapeutics stock for Q1 2017, up 15,047% quarter-over-quarter.
  • 12 funds opened new Viridian Therapeutics positions in Q1 2017 and 3 closed out, a net change of +9 holders.
  • The largest Viridian Therapeutics buyer in Q1 2017 was Fidelity Investments, an estimated $35.9M added.
  • The largest Viridian Therapeutics seller in Q1 2017 was Renaissance Technologies, an estimated $53K sold.

Based on aggregated 13F filings for Q1 2017.